Meropi Athanasiou - Concepedia

Author

Meropi Athanasiou

Science Applications International Corporation (United States)

Also Known As

M Athanasiou, M. A. Athanasiou, M. Athanasiou, Meropi Athanasiou

Publications

744

Citations

H-Index

Concepts

All Affiliations

Science Applications International Corporation (United States)National Cancer Institute Frederick National Laboratory for Cancer Research University of Crete National Institutes of Health

About

Meropi Athanasiou is an author at Science Applications International Corporation (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	620
2	Cell Biology	9	9	620
3	Immunology	2	2	115
4	Molecular Biology	2	2	96
5	Natural Sciences	1	1	58

Meropi Athanasiou

Publications

695

Citations

H-Index

Page 1

	Year	Citations
ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. Dionyssios N. Sgouras, Meropi Athanasiou, Gregory Beal, The EMBO Journal Transcriptional RegulationSignal TransductionMitogenic StimulationSignaling PathwayCell Regulation	1995	171
Mutation of SENP1/SuPr-2 Reveals an Essential Role for Desumoylation in Mouse Development Taihei Yamaguchi, Prashant Sharma, Meropi Athanasiou, Molecular and Cellular Biology GeneticsGenomic MechanismEpigeneticsCovalent ModificationCell Signaling	2005	97
FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells Meropi Athanasiou, George Mavrothalassitis, Lin Sun-Hoffman, Leukemia Developmental BiologyHematologyHuman Hematopoietic CellsBlood CellMyelopoiesis	2000	90
Increased expression of the ETS-related transcription factor FLI-1/ERGB correlates with and can induce the megakaryocytic phenotype. Meropi Athanasiou, Peter A. Clausen, G J Mavrothalassitis, PubMed Tpa TreatmentHematological MalignancyTranscriptional RegulationTpa-treated K562 CellsMegakaryocytic Phenotype	1996	89
Cutting Edge: Bone Morphogenetic Protein Antagonists Drm/Gremlin and Dan Interact with Slits and Act as Negative Regulators of Monocyte Chemotaxis Bo Chen, Donald G. Blair, Sergei Y. Plisov, The Journal of Immunology	2004	63
Drm/Gremlin transcriptionally activates p21Cip1 via a novel mechanism and inhibits neoplastic transformation Meropi Athanasiou, Qiuping Gu, Donald G. Blair Biochemical and Biophysical Research Communications Transcriptional RegulationNovel MechanismSignaling PathwayCell RegulationMedicine	2002	58
Role of Ets/Id proteins for telomerase regulation in human cancer cells Xiaodong Xiao, Meropi Athanasiou, Igor A. Sidorov, Experimental and Molecular Pathology Oncogenic AgentTelomerase RegulationMedicineMolecular BiologyEts/id Proteins	2003	38
Oncogenicity of DNA in vivo: Tumor induction with expression plasmids for activated H-ras and c-myc Sheng Li, Fang Cai, Yong Zhu, Biologicals Activated H-rasOncogenic AgentMedicineExpression PlasmidsCancer Genetics	2008	36
ETS-1 induces increased expression of erythroid markers in the pluripotent erythroleukemic cell lines K562 and HEL P Prætorious Clausen, Meropi Athanasiou, Z Chen, Leukemia ImmunologyBlood CellEts-1 InducesCell ProliferationErythroid Markers	1997	26
Suppression of the Ewing’s sarcoma phenotype by FLI1/ERF repressor hybrids Meropi Athanasiou, Lionel Le Gallic, Dennis K. Watson, Cancer Gene Therapy Sarcoma PhenotypeMedicinePathologyCancer Cell BiologyTumor Suppressor	2000	15

Page 1